{"analyses":[{"ciLowerLimit":"0.761","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.677","estimateComment":"HR obtained by unadjusted Cox's proportional hazard regression model stratified by age, ISS and prior lines of therapy. HR \\<1 was deemed to indicate longer survival time in Ixazomib + Dexamethasone arm as compared to Pomalidomide + Dexamethasone arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.265","paramType":"Hazard Ratio (HR)","paramValue":"1.427","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% confidence interval (CI) were not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"13.963","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"10.973","upperLimit":"NA","value":"18.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause, up to 3 years are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized. Participants without documented death at the time of analysis were censored at the date last known to be alive.","reportingStatus":"POSTED","timeFrame":"From date of randomization to death due to any cause (Up to approximately 3 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}